PLEASANTON, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Workday, Inc. (NASDAQ: WDAY), a leader in enterprise cloud applications for finance and human resources, today announced it will host Workday Rising from Oct. 1 - 4 at the Mandalay Bay in Las Vegas. …
MADISON, Wis., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces today that …
REDWOOD CITY, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various conditions and for …
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “New Technologies May Turn Arkansas into a Lithium Superpower,” featuring Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: …
PHOENIX, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Argentum 47, Inc. (OTC: ARGQ), (the “Company”) announced CEO Peter Smith’s interview on Uptick Newswire’s “Stock Day” Podcast. Everett Jolly invited, Peter Smith, CEO of Argentum 47, Inc., to the “Stock Day” …
VAN NUYS, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq: CPST), the world’s leading clean technology manufacturer of microturbine energy systems, announced today it continues to expand into the …
Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network PARSIPPANY, NJ, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Interpace …
EMERYVILLE, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, has monitored …
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the presentation of two Mayo …
SHANGHAI, China, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Huazhu Group Limited (NASDAQ:HTHT) (“Huazhu” or the “Company”), a leading and fast-growing multi-brand hotel group in China, today provided updates on the investigation status of the alleged information …
Rockville, MD, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Incorporation of technological up-to-date mobile accessories in automobiles is slated to be heavily influenced by spate of unstoppable innovation in the automotive industry. The call for seamless cross- …
Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local …
Hexyon has been studied in several countries worldwide in 12 main studies involving over 3,400 children between six weeks and two years of age who were given three doses of the vaccine during their first six months of life according to different local …
There were six main studies of Multaq in adults who had had atrial fibrillation. The first three studies, involving, 1,411 patients, found that Multaq was more effective than placebo (a dummy treatment) at preventing atrial fibrillation. The main measure …
There were six main studies of Multaq in adults who had had atrial fibrillation. The first three studies, involving, 1,411 patients, found that Multaq was more effective than placebo (a dummy treatment) at preventing atrial fibrillation. The main measure …
Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children. The demonstration of the benefit of Ziagen is mainly based on results of studies performed with …
Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children. The demonstration of the benefit of Ziagen is mainly based on results of studies performed with …
Replacement therapy in adults, children and adolescents (0-18 years) in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom …
Replacement therapy in adults, children and adolescents (0-18 years) in: primary immunodeficiency syndromes with impaired antibody production; hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom …
Lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years. The choice of lopinavir/ …
